Detecting Atrial Fibrillation in Stroke Patients Using Wearable Devices
Clinical Implication of Atrial Fibrillation Detection Using Wearable Device in Patients With Cryptogenic Stroke - The Comparison Between Short-term Continuous Patch and Long-term Discontinuous Monitoring
This study is testing three different ways to use wearable devices to find hidden atrial fibrillation in stroke patients to help prevent future strokes.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 600 (estimated) |
| Ages | 20 Years to 80 Years |
| Sex | All |
| Sponsor | Ewha Womans University Mokdong Hospital Academic / other |
| Locations | 9 sites (Yongin, Gyeonggi-do and 8 other locations) |
| Trial ID | NCT04624646 on ClinicalTrials.gov |
What this trial studies
This study aims to improve the detection of atrial fibrillation in patients who have experienced a cryptogenic stroke by comparing three different monitoring methods: discontinuous ECG monitoring three times a day, continuous single-lead ECG patch monitoring for 72 hours, and the conventional 24-hour Holter monitoring. The goal is to identify hidden atrial fibrillation that may increase the risk of subsequent strokes or systemic embolism. By utilizing wearable technology, the study seeks to enhance patient outcomes through timely intervention and appropriate anticoagulant treatment.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with newly diagnosed brain infarction who have no prior history of atrial fibrillation.
Not a fit: Patients who are unable to use the KardiaMobile system, either independently or with assistance, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better detection and management of atrial fibrillation in stroke patients, potentially reducing the risk of future strokes.
How similar studies have performed: Other studies have shown promise in using wearable devices for monitoring atrial fibrillation, indicating that this approach is gaining traction in clinical practice.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Newly diagnosed brain infarction * No history and diagnosis of atrial fibrillation at the time of admission * Rejected implantable loop recorder * Informed consent Exclusion Criteria: * Cannot use KardiaMobile system alone or with the help of others
Where this trial is running
Yongin, Gyeonggi-do and 8 other locations
- Yonsei University Health System, Yongin Severance Hospital — Yongin, Gyeonggi-do, Korea, Republic of (Not_yet_recruiting)
- Ewha Womans University Seoul Hospital — Gangseo, Seoul, Korea, Republic of (Recruiting)
- Hanyang University Seoul Hospital — Seongdong, Seoul, Korea, Republic of (Recruiting)
- Ewha Womans University Mokdong Hospital — Yangcheon, Seoul, Korea, Republic of (Recruiting)
- Daegu Catholic University Medical Center — Daegu, Korea, Republic of (Recruiting)
- Gachon University Gil Hospital — Incheon, Korea, Republic of (Recruiting)
- Kyung Hee University Hospital — Seoul, Korea, Republic of (Recruiting)
- Yonsei University Health System, Severance Hospital — Seoul, Korea, Republic of (Recruiting)
- Korea University Guro Hospital — Seoul, Korea, Republic of (Recruiting)
Study contacts
- Principal investigator: Junbeom Park, M.D., PhD. — Ewha Womans University Mokdong Hospital
- Study coordinator: Junbeom Park, M.D.,PhD
- Email: parkjb@ewha.ac.kr
- Phone: +821035399822
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.